{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:53:47Z","timestamp":1768416827644,"version":"3.49.0"},"reference-count":73,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:p>Oncogenes play a crucial part in human cancer development, and when particular drugs obstruct the proteins produced by these oncogenes, the tumoural process can be ceased. For instance, in chronic myeloid leukaemia (CML), all pathological traits are associated with a single oncogene, <jats:italic>BCR-ABL1<\/jats:italic>. CML is a triphasic cancerous disorder of haematopoietic stem cells, marked by a balanced translocation between chromosomes 9 and 22, leading to the genesis of a Philadelphia chromosome encompassing the <jats:italic>BCR-ABL1<\/jats:italic> fusion gene. This fusion oncogene further produces a constitutive active tyrosine kinase protein, enhancing the downstream signalling pathways and constitutes cancer. The treatment for CML has been entirely altered from chemotherapy and immunotherapy to targeted therapy with the emergence of tyrosine kinase inhibitors (TKIs) which inhibit <jats:italic>BCR-ABL1<\/jats:italic> kinase activity. However, the inhibitory mechanism of TKIs is constrained by <jats:italic>BCR-ABL1<\/jats:italic> dependent and independent resistance mechanisms, prompting the exploration of novel therapeutics through extensive clinical trials to develop next-generation drugs with enhanced potency. The persistent challenges posed by CML have motivated researchers to seek innovative strategies for its eradication, such as the application of the genome editing tool CRISPR\/Cas9. This review provides insights into existing CML diagnoses, treatment modalities, resistance mechanisms, drugs under trial phases and new potential therapeutic drugs. Furthermore, the review looks ahead to a visionary perspective wherein the CRISPR\/Cas9 approach holds the potential to evolve into a prospective curative measure for CML.<\/jats:p>","DOI":"10.25259\/ijmr_1716_22","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T19:51:49Z","timestamp":1722714709000},"page":"455-467","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Insights into existing and futuristic treatment approach for chronic myeloid leukaemia"],"prefix":"10.25259","volume":"159","author":[{"given":"Sourabh","family":"Tyagi","sequence":"first","affiliation":[{"name":"Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Singh","sequence":"additional","affiliation":[{"name":"School of Biotechnology, Jawaharlal Nehru University, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Sharma","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Division, Indian Council of Medical Research, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India"},{"name":"School of Biotechnology, Jawaharlal Nehru University, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant Ritturaj","family":"Kushwaha","sequence":"additional","affiliation":[{"name":"Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India"},{"name":"School of Biotechnology, Jawaharlal Nehru University, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"10.25259\/ijmr_1716_22\/ref-1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J Clin"},{"key":"10.25259\/ijmr_1716_22\/ref-2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","article-title":"An overview and update of chronic myeloid leukemia for primary care physicians","volume":"36","author":"Granatowicz","year":"2015","journal-title":"Korean J Fam Med."},{"key":"10.25259\/ijmr_1716_22\/ref-3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl.","year":"1999","journal-title":"N Engl J Med"},{"key":"10.25259\/ijmr_1716_22\/ref-4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","article-title":"Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries","volume":"37","author":"Mendizabal","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.25259\/ijmr_1716_22\/ref-6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/GO.21.00194","article-title":"Magnitude and temporal trend of the chronic myeloid leukemia: On the basis of the Global Burden of Disease Study 2019","volume":"7","author":"Hu","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/ajh.24381","article-title":"Monitoring disease burden in chronic myeloid leukemia: Past, present, and future","volume":"91","author":"Egan","year":"2016","journal-title":"Am J Hematol"},{"key":"10.25259\/ijmr_1716_22\/ref-9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9123865","article-title":"Molecular testing in CML between old and new methods: Are we at a turning point?","volume":"9","author":"Soverini","year":"2020","journal-title":"J Clin Med"},{"key":"10.25259\/ijmr_1716_22\/ref-13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.25259\/ijmr_1716_22\/ref-14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.25259\/ijmr_1716_22\/ref-15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs. imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-17","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.25259\/ijmr_1716_22\/ref-18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-19","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"Le Coutre","year":"2012","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-21","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-Study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-25","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.25259\/ijmr_1716_22\/ref-26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-29","first-page":"1","article-title":"ENESTOP 192-wk results: Durability and impact on quality of life of treatment-free remission (TFR) following second-line (2L) nilotinib (NIL) in patients (PTS) with chronic myeloid leukemia (CML)","volume":"2","author":"Mahon","year":"2019","journal-title":"Hemasphere"},{"key":"10.25259\/ijmr_1716_22\/ref-30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11899-019-0496-8","article-title":"Treatment-free remission in CML: The US perspective","volume":"14","author":"Guru Murthy","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.25259\/ijmr_1716_22\/ref-31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrclinonc.2017.11","article-title":"Targeted therapies: Remembrance of things past - Discontinuation of second-generation TKI therapy for CML","volume":"14","author":"Hughes","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jmoldx.2018.03.002","article-title":"Droplet digital PCR is a robust tool for monitoring minimal residual disease in adult Philadelphia-positive acute lymphoblastic leukemia","volume":"20","author":"Coccaro","year":"2018","journal-title":"J Mol Diagnostics"},{"key":"10.25259\/ijmr_1716_22\/ref-33","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/s18041271","article-title":"dPCR: A technology review","volume":"18","author":"Quan","year":"2018","journal-title":"Sensors (Switzerland)"},{"key":"10.25259\/ijmr_1716_22\/ref-34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jmoldx.2013.10.007","article-title":"Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR","volume":"16","author":"Jennings","year":"2014","journal-title":"J Mol Diagnostics"},{"key":"10.25259\/ijmr_1716_22\/ref-35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","article-title":"Quantitative assessment of the BCR-ABL transcript using the cepheid Xpert BCR-ABL Monitor assay","volume":"131","author":"Dufresne","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.25259\/ijmr_1716_22\/ref-36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2016.08.007","article-title":"Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia","volume":"49","author":"Gerrard","year":"2016","journal-title":"Leuk Res"},{"key":"10.25259\/ijmr_1716_22\/ref-37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","article-title":"Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol Cancer"},{"key":"10.25259\/ijmr_1716_22\/ref-38","first-page":"2043","article-title":"Molecular response to imatinib and its correlation with mRNA expression levels of imatinib influx transporter (OCT1) in Indian Chronic Myeloid Leukemia patients","volume":"18","author":"Chhikara","year":"2017","journal-title":"Asian Pacific J Cancer Prev"},{"key":"10.25259\/ijmr_1716_22\/ref-39","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: Is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.leukres.2014.12.008","article-title":"Drug transporters play a key role in the complex process of Imatinib resistance in vitro","volume":"39","author":"Alves","year":"2015","journal-title":"Leuk Res"},{"key":"10.25259\/ijmr_1716_22\/ref-41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the Efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.25259\/ijmr_1716_22\/ref-42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.febslet.2004.03.123","article-title":"ABCG2 - A transporter for all seasons","volume":"567","author":"Sarkadi","year":"2004","journal-title":"FEBS Lett"},{"key":"10.25259\/ijmr_1716_22\/ref-43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.25259\/ijmr_1716_22\/ref-44","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-45","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-46","doi-asserted-by":"publisher","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.25259\/ijmr_1716_22\/ref-47","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"key":"10.25259\/ijmr_1716_22\/ref-48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature07849","article-title":"Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions","volume":"458","author":"Cook","year":"2009","journal-title":"Nature"},{"key":"10.25259\/ijmr_1716_22\/ref-49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.25259\/ijmr_1716_22\/ref-50","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.25259\/ijmr_1716_22\/ref-51","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of \u03b2-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.25259\/ijmr_1716_22\/ref-52","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cbin.11557","article-title":"Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K\/c-Myc axis on panobinostat cytotoxicity","volume":"45","author":"Zehtabcheh","year":"2021","journal-title":"Cell Biol Int"},{"key":"10.25259\/ijmr_1716_22\/ref-53","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2015.329","article-title":"Mtss1 is a critical epigenetically regulated tumor suppressor in CML","volume":"30","author":"Schemionek","year":"2016","journal-title":"Leukemia"},{"key":"10.25259\/ijmr_1716_22\/ref-54","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"San Jos\u00e9-Eneriz","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.25259\/ijmr_1716_22\/ref-55","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: Small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat Rev Genet"},{"key":"10.25259\/ijmr_1716_22\/ref-56","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth","volume":"6","author":"Agirre","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.25259\/ijmr_1716_22\/ref-57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-10-1","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Machov\u00e1 Polakov\u00e1","year":"2011","journal-title":"Mol Cancer"},{"key":"10.25259\/ijmr_1716_22\/ref-58","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"},{"key":"10.25259\/ijmr_1716_22\/ref-59","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","author":"Venturini","year":"2007","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-60","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.25259\/ijmr_1716_22\/ref-61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","article-title":"Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients","volume":"9","author":"Chandrasekhar","year":"2019","journal-title":"Sci Rep"},{"key":"10.25259\/ijmr_1716_22\/ref-62","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/blood-2019-127951","article-title":"PF-114: A 4th generation tyrosine kinase-inhibitor for chronic phase chronic myeloid leukaemia including BCRABL1T315I","volume":"134","author":"Turkina","year":"2019","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood.2019002085","article-title":"An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3rd generation of BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI resistant chronic myeloid leukemia","volume":"134","author":"Jiang","year":"2019","journal-title":"Blood"},{"key":"10.25259\/ijmr_1716_22\/ref-64","doi-asserted-by":"publisher","first-page":"26027","DOI":"10.18632\/oncotarget.15215","article-title":"The CRISPR\/Cas9 system efficiently reverts the tumorigenic ability of BCR\/ABL in vitro and in a xenograft model of chronic myeloid leukemia","volume":"8","author":"Garc\u00eda-Tu\u00f1\u00f3n","year":"2017","journal-title":"Oncotarget"},{"key":"10.25259\/ijmr_1716_22\/ref-65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0664-4","article-title":"Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of BCR-ABL oncogene with zinc finger nucleases","volume":"37","author":"Huang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.25259\/ijmr_1716_22\/ref-66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0216674","article-title":"Splice donor site sgRNAs enhance CRISPR\/ Cas9-mediated knockout efficiency","volume":"14","author":"Garc\u00eda-Tu\u00f1\u00f3n","year":"2019","journal-title":"PLoS One"},{"key":"10.25259\/ijmr_1716_22\/ref-67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-018-1018-6","article-title":"Efficient disruption of BCR-ABL gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells","volume":"38","author":"Luo","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.25259\/ijmr_1716_22\/ref-68","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","article-title":"In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells","volume":"11","author":"Martinez-Lage","year":"2020","journal-title":"Nat Commun"},{"key":"10.25259\/ijmr_1716_22\/ref-69","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-1-4939-3661-8_13","article-title":"Chronic myeloid leukemia (CML) mouse model in translational research","volume":"1438","author":"Peng","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.25259\/ijmr_1716_22\/ref-70","doi-asserted-by":"publisher","first-page":"44061","DOI":"10.18632\/oncotarget.6392","article-title":"ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts","volume":"6","author":"Valletta","year":"2015","journal-title":"Oncotarget"},{"key":"10.25259\/ijmr_1716_22\/ref-71","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature.2016.20988","article-title":"CRISPR gene-editing tested in a person for the first time","volume":"539","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"key":"10.25259\/ijmr_1716_22\/ref-72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061399","article-title":"ABL genomic editing sufficiently abolishes oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo","volume":"12","author":"Chen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.25259\/ijmr_1716_22\/ref-74","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: Applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol"},{"key":"10.25259\/ijmr_1716_22\/ref-75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fbioe.2022.895713","article-title":"Viral vectors for the in vivo delivery of CRISPR components: Advances and challenges","volume":"10","author":"Asmamaw Mengstie","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.25259\/ijmr_1716_22\/ref-76","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1126\/science.aas9129","article-title":"Engineered CRISPR-Cas9 nuclease with expanded targeting space","volume":"361","author":"Nishimasu","year":"2018","journal-title":"Science"},{"key":"10.25259\/ijmr_1716_22\/ref-77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature26155","article-title":"Evolved Cas9 variants with broad PAM compatibility and high DNA specificity","volume":"556","author":"Hu","year":"2018","journal-title":"Nature"}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/insights-into-existing-and-futuristic-treatment-approach-for-chronic-myeloid-leukaemia\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/insights-into-existing-and-futuristic-treatment-approach-for-chronic-myeloid-leukaemia\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T03:29:58Z","timestamp":1734665398000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/insights-into-existing-and-futuristic-treatment-approach-for-chronic-myeloid-leukaemia\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":73,"alternative-id":["10.25259\/ijmr_1716_22"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_1716_22","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"article-number":"455"}}